Hit Identification Against Candida Albicans: Design, Synthesis, Molecular Docking and Biological Evaluation of Hybrid Styryl-Quinoxaline Based Analogues.

Document Type : Original Article

Authors

1 Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, October University for Modern Science and Arts (MSA), Cairo, 12611, Egypt

2 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, 11566, Egypt

3 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Cairo, 12611, Egypt

4 Department of Microbiology and Immunology, Faculty of Pharmacy, University of Sadat City, Sadat city, Menoufia, 32897,Egypt

5 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, 11566, Egyp

Abstract

The occurrence of invasive fungal infections (IFIs) and the incidence of resistant fungal pathogens have increased dramatically, leading to high morbidity and mortality especially with immune-compromised patients. Owing to their multifunctional pharmacological profiles, quinoxalines attract widespread attention being a part of several biologically and technologically relevant compounds. Herein, we report the design, synthesis, structural characterization, and biological screening of a series of new quinoxaline-based scaffolds. The antimicrobial activities of the synthesized compounds were assessed against a panel of bacterial species as well as representative fungi. Interestingly, N-(3-chlorophenyl)-2-(3-(2-hydroxystyryl)quinoxalin-2-yl) hydrazinecarboxamide (3a) displayed significant antifungal activity against Candida albicans (MIC50 ≤0.25 µg/mL) compared to that of the reference drug fluconazole (MIC50 =0.125 µg/mL). Molecular docking studies showed that the potency of our compounds could be attributed to the inhibition of fungal squalene epoxidase enzyme. Additionally, all synthesized compounds were almost neither toxic to human embryonic kidney cells (CC50 >32.0 µg/mL) nor to human red blood cells (HC10 >32.0 µg/mL). The above finding results suggested that compounds 3a is a promising lead compound that merits further optimization and development as antifungal candidate.

Keywords


Volume 66, Issue 13 - Serial Number 13
Special Issue: Applied Chemistry for Greener Life and Sustainability
December 2023
Pages 1295-1308
  • Receive Date: 11 April 2023
  • Revise Date: 20 May 2023
  • Accept Date: 23 May 2023